Factors influencing “no treatment” decisions in advanced stage cancers.

Authors

null

Ogheneyoma Akpoviroro

Geisinger Northeast, Wilkes Barre, PA

Ogheneyoma Akpoviroro, Oghenetejiro Princess Akpoviroro, Queeneth Uwandu, Kristena Yossef, Steven Suastegui, Myriam Castagne, Elga Rodrigues, Brian Bolden, Wasique Mirza

Organizations

Geisinger Northeast, Wilkes Barre, PA, Mater Dei Hospital, Department of Medicine, Msida, Malta, Boston University, Boston, MA, Geisinger Health Systems, Wilkes-Barre, PA

Research Funding

Other
Geisinger.

Background: Several studies have attempted to explore treatment refusal in patients with cancer (CA). We performed a study that focused on patients with advanced CAs, characterizing those in this group that refused therapy. Based on this study, we sought to determine if some variables significantly correlated with ‘no treatment’ decisions, compared with a group of similar patients who accepted therapy. Methods: Our inclusion criteria were patients aged 18-75 years, diagnosed with stage IV CAs (per the American Joint Committee on Cancer staging) between 1/1/2010 and 12/31/2015 and refused therapy (Cohort 1). A randomly selected group of patients with stage IV CAs who accepted treatment in the same timeframe were used for comparison (Cohort 2). We used Proc SurveySelect and a simple random sampling method to create Cohort 2. Geisinger Health System’s data was used. Results: We found 508 patients for cohort 1, and 100 patients for cohort 2. The significance level was < 0.05. Female sex was associated with treatment acceptance (51/100, 51.0%) compared with refusal (201/508, 39.6%); p = 0.03. There was no association between treatment decision and race, marital status, BMI, tobacco use, previous CA history, or family CA history. Government-funded insurance was associated with therapy refusal (337/508, 66.3%) than acceptance (35/100, 35.0%); p < 0.0001. Cohort 1 had an older population compared with cohort 2 (p < 0.0001). The mean age of cohort 1 was 63.1 years (standard deviation (σ) 8.1), and 59.2 (σ 9.9) in cohort 2. The most common malignancy site in both cohorts was the respiratory system but this was not related to treatment decisions. Patients with pancreatic CA tended to refuse treatment (p = 0.0009). Only 19.1% (97/508) in cohort 1 were referred to palliative medicine, with 18% (18/100) in cohort 2; p = 0.8. There was an insignificant trend for patients who accepted treatment to have more comorbidities per the Charleston Comorbidity Index (CCI) (p = 0.08). The mean CCI in cohort 1 was 6.5 (σ 3.7), and 8.0 (σ 3.9) in cohort 2. Treatment of psychiatric disorders after CA diagnosis was inversely associated with treatment refusal (p < 0.0001). Conclusions: Male sex, older age, government-funded health insurance, and pancreatic CAs were associated with treatment refusal in advanced CA patients. Those who refused treatment were not increasingly referred to palliative medicine. Treatment of psychiatric disorders after CA diagnosis was associated with treatment acceptance.

Variables
Cohort 1

n = 508

n (%)
Cohort 2

n = 100

n (%)
Total

n = 608

n (%)
p-value
Sex



0.03391
Female
201 (39.6)
51 (51.0)
252 (41.4)

Male
307 (60.4)
49 (49.0)
356 (58.6)

Insurance



<.00011
Government-funded
337 (66.3)
35 (35.0)
372 (61.2)

Private
164 (32.3)
65 (65.0)
229 (37.7)

None
7 (1.4)
0 (0.0)
7 (1.2)

ICDO Site



0.00091
Pancreatic
86 (16.9)
4 (4.0)
90 (14.8)

Palliative Referral



0.79841
No
411 (80.9)
82 (82.0)
493 (81.1)

Yes
97 (19.1)
18 (18.0)
115 (18.9)

1Chi-Square p-value.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2022 ASCO Quality Care Symposium

Session Type

Poster Session

Session Title

Poster Session A

Track

Cost, Value, and Policy,Health Care Access, Equity, and Disparities,Patient Experience

Sub Track

Access to and Utilization of Palliative and Supportive Care

Citation

J Clin Oncol 40, 2022 (suppl 28; abstr 77)

DOI

10.1200/JCO.2022.40.28_suppl.077

Abstract #

77

Poster Bd #

C10

Abstract Disclosures

Similar Abstracts

Abstract

2023 ASCO Quality Care Symposium

Receipt of only palliative care among patients with advanced-stage head and neck cancer.

First Author: Dina K Abouelella